跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NSI-1
首页
药物
NSI-1
NSI-1
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo
US 7262270 B2
申请人: CHILDRENS MEDICAL CENTER
优先权: 2003
US
2 件公开
Silicon compound and method of manufacturing integrated circuit device using the same
US 12649716 B2
申请人: SAMSUNG ELECTRONICS CO LTD
优先权: 2022
US
2 件公开
Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent
US 12233059 B2
申请人: ALTO NEUROSCIENCE INC
优先权: 2024
US
2 件公开
US 12208096 B2
申请人: ALTO NEUROSCIENCE INC
优先权: 2024
US
2 件公开
Antimicrobial coatings for medical applications
US 2005008763 A1
申请人: SCHACHTER STEVEN C
优先权: 2003
US
Composition For The Preparation of Cosmetics, Cosmetic, and Method For the Preparation Of Water-Containing Cosmetics
US 2010112017 A1
申请人: MIZUTANI YASUE
优先权: 2006
US
HAIR CARE COMPOSITION COMPRISING ALKYL-MODIFIED SILOXANE
US 2013022567 A1
申请人: MURRAY ANDREW MALCOLM
优先权: 2010
US
Methods of treating depression patients with poor cognitive function and choices for other patients that benefit from benzylpiperazine-aminopyridine agents
CN 117396207 A
申请人: OUTOT NEUROSCIENCE INC
优先权: 2021
CN
GLOBULAR NANOSTRUCTURES HAVING AN ANCHORING LAYER
US 20250186635 A1
申请人: SPAGO NANOMEDICAL AB
优先权: 2022
US
Use of benzylpiperazine-aminopyridine agents for effective treatment of depression in patients with learning and/or memory impairment or certain EEG characteristics
CN 120435292 A
申请人: OUTOT NEUROSCIENCE INC
优先权: 2022
CN
METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT
US 20250177386 A1
申请人: ALTO NEUROSCIENCE INC
优先权: 2025
US
药物
反馈
